The Clinical Research Office Shared Resource (CRO) oversees the review, initiation, conduct, and safety monitoring of clinical trials at the Norris Cotton Cancer Center. The CRO components are 1) an administrative staff including the Shared Resource Director, an Associate Director, an Assistant Director, a financial manager, and a protocol assistant; 2) the Protocol-Specific Research Support staff, comprising a research pharmacist, a pharmacy technician, two research registered nurses, and 16 clinical research assistants / coordinators; 3) the Protocol Review and Monitoring System, consisting of the Clinical Cancer Research Committee (CCRC) and the Safety and Data Monitoring Committee (SDMC); and 4) the Dartmouth-Hitchcock Tumor Registry, staffed by three registrars. Although DHMC and the NCCC have designated the CRO as the office responsible for administrative oversight of all aspects of clinical cancer research including the hospital tumor registry, our request for CCSG funding is for the more narrowly defined functions of this Shared Resource related to support peer-reviewed clinical trials of cancer treatment and chemoprevention. The CRO maintains local Dartmouth Medical School studies, working group studies, cooperative group protocols, and industrial trials. It is responsible for assisting in formatting protocols, writing consent forms, maintaining Institutional Review Board and SDMC records, developing budgets, assessing impact on institutional resources, activating protocols, assessing eligibility, developing data collection forms and databases, and collecting and managing data. Prioritization of clinical trials is determined within the 12 NCCC Clinical Oncology Groups, with approval by the CCRC. The CRO acts as a checkpoint prior to activation of protocols to ensure that all appropriate administrative aspects of trials are complete. Charge-back policies of the CRO accurately reflect usage, and are based on patient accrual to reviewed and approved protocols.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dartmouth College
United States
Zip Code
Gacerez, Albert T; Hua, Casey K; Ackerman, Margaret E et al. (2018) Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression. Cancer Immunol Immunother 67:749-759
Onega, T; Zhu, W; Weiss, J E et al. (2018) Preoperative breast MRI and mortality in older women with breast cancer. Breast Cancer Res Treat 170:149-157
Vergo, Maxwell T; Pinkson, Briane M; Broglio, Kathleen et al. (2018) Immediate Symptom Relief After a First Session of Massage Therapy or Reiki in Hospitalized Patients: A 5-Year Clinical Experience from a Rural Academic Medical Center. J Altern Complement Med 24:801-808
Varn, Frederick S; Schaafsma, Evelien; Wang, Yue et al. (2018) Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs. Cancer Res 78:6413-6423
Hill, Deirdre A; Haas, Jennifer S; Wellman, Robert et al. (2018) Utilization of breast cancer screening with magnetic resonance imaging in community practice. J Gen Intern Med 33:275-283
Lott, Jason P; Boudreau, Denise M; Barnhill, Ray L et al. (2018) Population-Based Analysis of Histologically Confirmed Melanocytic Proliferations Using Natural Language Processing. JAMA Dermatol 154:24-29
Jackson, Brian P (2018) Low level determination of gallium isotopes by ICP-QQQ. J Anal At Spectrom 33:897-900
Rahme, Gilbert J; Luikart, Bryan W; Cheng, Chao et al. (2018) A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma. Neuro Oncol 20:332-342
Barr, Fiona D; Ochsenbauer, Christina; Wira, Charles R et al. (2018) Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunol 11:1420-1428
Sergent, P A; Plummer, S F; Pettus, J et al. (2018) Blocking the VISTA pathway enhances disease progression in (NZB?×?NZW) F1 female mice. Lupus 27:210-216

Showing the most recent 10 out of 1911 publications